SAN DIEGO, CA--(Marketwire - Feb 14, 2013) - With the advent of receiving Shonin approval in Japan, Naviscan's distributor, SCETI K. K. has placed an order for two additional high-resolution, organ-specific PET scanners. In addition, ASRAS Medical, Naviscan's distributor in Thailand, was awarded an order for one system by Rajavithi Hospital in Bangkok. All three systems are scheduled for shipment in the 1st calendar quarter of 2013, for installation early in the 2nd calendar quarter of the year.
The Naviscan Positron Emission Mammography (PEM) scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early breast cancer diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions -- what researchers term "specificity."
"In the brief time since the December 2012 Radiological Society of North America (RSNA) meeting, we have seen a rapid increase in acceptance and demand for our high-resolution, organ-specific molecular imaging system in the global market. Nowhere has this been more evident than in Asia," said Paul J. Mirabella, CEO, Naviscan. "As we continue to meet the appropriate regulatory and reimbursement requirements in each country and as our installed base of valued customers continues to publish the clinical benefits of our technology, we expect this rapid rate of adoption to continue."
''After obtaining a market approval from the Japanese PMDA in mid 2012, we are pleased to be making PEM available to the largest number of Japanese breast physicians. Besides one system being used at Yuai Clinic in Yokohama for the past two years, SCETI plans to install two additional PEM scanners in the forthcoming months," stated Fabien Reyjal, President, SCETI K.K. "The Japanese market is growing and there is a significant need for innovative approaches to breast imaging. We are excited to continue expanding our PEM network accordingly."
"We at Asras Medical Co., Ltd., Thailand, are delighted to be able to bring the most advanced imaging technology to the medical professionals that provide treatment to patients affected with breast cancer," stated Mrs. Pornthip Champathin, Managing Director, Asras Medical Co., Ltd.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.